Randomized phase II trial of carboplatin + nab-paclitaxel versus cisplatin + gemcitabine for chemotherapy-naïve squamous cell carcinoma: North Japan lung cancer study group 1302

被引：0

作者：

Yosuke Kawashima

Toshiyuki Harada

Yuka Fujita

Taku Nakagawa

Kana Watanabe

Naoto Morikawa

Kei Takamura

Kenya Kanazawa

Tomoya Kuda

Kazuhiro Usui

Akimasa Sekine

Akira Inoue

Shunichi Sugawara

机构：

[1] Sendai Kousei Hospital,Department of Pulmonary Medicine

[2] JCHO Hokkaido Hospital,Department of Respiratory Medicine

[3] National Hospital Organization Asahikawa Medical Center,Department of Respiratory Medicine

[4] Omagari Kosei Medical Center,Department of Thoracic Surgery

[5] Miyagi Cancer Center,Department of Respiratory Medicine

[6] Iwate Medical University School of Medicine,Division of Pulmonary Medicine, Allergy, and Rheumatology

[7] Obihiro Kosei Hospital,Department of Pulmonary Medicine

[8] Fukushima Medical University School of Medicine,Department of Pulmonary Medicine

[9] Naha City Hospital,Department of Respiratory Medicine

[10] NTT Medical Center Tokyo,Division of Respirology

[11] Kanagawa Cardiovascular and Respiratory Center,Department of Respiratory Medicine

[12] Tohoku University School of Medicine,Department of Palliative Medicine

来源：

International Journal of Clinical Oncology | 2021年 / 26卷

关键词：

Carboplatin; Albumin-bound paclitaxel; Cisplatin; Gemcitabine; Chemotherapy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：515 / 522

页数：7

共 50 条

[41] Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial
Denise A. Yardley
Adam Brufsky
Robert E. Coleman
Pierfranco F. Conte
Javier Cortes
Stefan Glück
Jean-Mark A. Nabholtz
Joyce O’Shaughnessy
Robert M. Beck
Amy Ko
Markus F. Renschler
Debora Barton
Nadia Harbeck
Trials, 16
[42] nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial
Gridelli, Cesare
Chen, Tianlei
Ko, Amy
O'Brien, Mary E.
Ong, Teng Jin
Socinski, Mark A.
Postmus, Pieter E.
DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 1445 - 1451
[43] Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR
Yoon Ji Choi
Dae Ho Lee
Chang Min Choi
Jung Shin Lee
Seung Jin Lee
Jin-Hee Ahn
Sang-We Kim
BMC Cancer, 15
[44] A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer
Villaruz, Liza C.
Cobo, Manuel
Syrigos, Konstantinos
Mavroudis, Dimitrios
Zhang, Wei
Kim, Jong Seok
Socinski, Mark A.
LUNG CANCER, 2019, 136 : 52 - 56
[45] Phase I/II Trial of Carboplatin, nab-Paclitaxel and Bevacizumab for Advanced Non-Squamous Non-Small Cell Lung Cancer: Results of Phase I Part
Ikeo, Satoshi
Nogami, Naoyuki
Kitajima, Hiromoto
Yoshioka, Hiroshige
Bessho, Akihiro
Kaira, Kyoichi
Kubo, Toshio
Murakami, Shuji
Watanabe, Koshiro
Kiura, Katsuyuki
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S905 - S905
[46] Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma
Fan, Yun
Jiang, Youhua
Zhou, Xinming
Chen, Qixun
Huang, Zhiyu
Xu, Yanjun
Gong, Lei
Yu, Haifeng
Yang, Haiyan
Liu, Jinshi
Lei, Tao
Zhao, Qiang
Mao, Weimin
ONCOTARGET, 2016, 7 (31) : 50624 - 50634
[47] Phase I/II Study of Carboplatin Plus Weekly Nab-Paclitaxel in Aged ≥75 Patients with Squamous-Cell Lung Cancer: TORG1322
Zenke, Y.
Niho, S.
Umemura, S.
Ishihara, M.
Ochiai, R.
Nogami, N.
Hosomi, Y.
Shimokawa, T.
Tokito, T.
Goto, Y.
Miura, Y.
Saito, H.
Hida, N.
Ikeda, S.
Tanaka, H.
Furuya, N.
Misumi, T.
Ohe, Y.
Okamoto, H.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S302 - S302
[48] Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial
Denise A. Yardley
Adam Brufsky
Robert E. Coleman
Pierfranco F. Conte
Javier Cortes
Stefan Glück
Jean-Mark A. Nabholtz
Joyce O’Shaughnessy
Robert M. Beck
Amy Ko
Markus F. Renschler
Debora Barton
Nadia Harbeck
Trials, 17
[49] A randomized phase II trial of cisplatin plus gemcitabine versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT0703)
Shin-ichi Fukumoto
Satoshi Oizumi
Masao Harada
Noriaki Sukoh
Kosuke Nakano
Satoshi Fuke
Jun Sakakibara-Konishi
Kei Takamura
Kenichiro Ito
Yuka Fujita
Yutaka Nishigaki
Toshiyuki Harada
Kenji Akie
Ichiro Kinoshita
Toraji Amano
Hiroshi Isobe
Hirotoshi Dosaka-Akita
Masaharu Nishimura
Cancer Chemotherapy and Pharmacology, 2020, 86 : 117 - 127
[50] A randomized phase II trial of cisplatin plus gemcitabine versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT0703)
Fukumoto, Shin-ichi
Oizumi, Satoshi
Harada, Masao
Sukoh, Noriaki
Nakano, Kosuke
Fuke, Satoshi
Sakakibara-Konishi, Jun
Takamura, Kei
Ito, Kenichiro
Fujita, Yuka
Nishigaki, Yutaka
Harada, Toshiyuki
Akie, Kenji
Kinoshita, Ichiro
Amano, Toraji
Isobe, Hiroshi
Dosaka-Akita, Hirotoshi
Nishimura, Masaharu
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (01) : 117 - 127

← 1 2 3 4 5 →